Revolution Medicines Receives FDA Approval and Launches RASONQUE
Revolution Medicines received U.S. FDA approval and launched RASONQUE (daraxonrasib) for adults with metastatic disease. The provided text does not specify the disease.
Related stories
Cathay Pacific Orders 14 Airbus Aircraft
Cathay Pacific ordered 14 Airbus aircraft to expand its fleet.
L impact | EQUITY | Nov 11, 2026, 05:47 AM UTC
IndiGo shares climb 4.3% to near one-year high
IndiGo rose 4.3% to 5,661.20 rupees as crude prices fell.
M impact | EQUITY | Nov 11, 2026, 05:37 AM UTC
KKR Acquires 50% Stakes in Vanguard West and Vanguard East
KKR has acquired a 50% equity stake in each of Vanguard West and Vanguard East, RWE AG says.
M impact | EQUITY | Nov 11, 2026, 05:31 AM UTC
Asian session market picture: S&P 500 +0.66%, Nasdaq 100 +1.4%; USD/JPY +0.02%, WTI +0.28%, 9984 leads volume
Asian session market picture. US index futures: S and P futures is up 0.66 percent, Nasdaq futures is up 1.4 percent, Dow futures is up 0.3 percent and Russell futures is up 0.51 p
M impact | EQUITY | Nov 11, 2026, 05:30 AM UTC
Airbus Wins Firm Order for 14 Additional Aircraft From Cathay Group
Airbus received a firm order for 14 additional aircraft from Cathay Group.
M impact | EQUITY | Nov 11, 2026, 05:26 AM UTC
TSMC Board Approves Up to $1 Billion Investment Plan in Anthropic and OpenAI
Taiwan Semiconductor Manufacturing said its board approved plans to invest up to $1 billion in Anthropic and OpenAI.
M impact | EQUITY | Nov 11, 2026, 05:23 AM UTC